PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms.

Trial Profile

PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms PARaGoN
  • Most Recent Events

    • 02 Jan 2017 Status changed from recruiting to completed.
    • 07 Jun 2016 Interim results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Nov 2015 Accrual to date is 25% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top